The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD25V Directed Antibody Drug Conjugate

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.

Please acknowledge that you understand this before proceeding.

Back

Molecule overview Clinical trials Scientific presentations

CD25V Directed Antibody Drug Conjugate

PF-08046032 is an investigational compound. Its safety and efficacy have not been established

Overview + Rationale Mechanism of Action Stage of Development

Share to an HCP

Overview + Rationale

PF-08046032 is a vedotin antibody-drug conjugate (ADC) engineered to target and deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment (TME) through direct cytotoxicity.
PF-08046032 directs delivery of the cytotoxic MMAE (monomethyl auristatin E) payload to cells expressing CD25 via affinity-detuned binding of the alpha chain of the IL-2 receptor, which is highly expressed on intratumoral Tregs and lymphoma cells.
In vitro, affinity-detuning enables targeting of CD25hi intratumoral Tregs while sparing peripheral Tregs.

Mechanism of Action

Stage of Development

Advanced Solid Tumors

Phase 1 Monotherapy and Combination (not initiated)

R/R Lymphomas

Phase 1 Monotherapy*

CD25V Directed Antibody Drug Conjugate

Geo Regions

CD25V Directed Antibody Drug Conjugate

Overview + Rationale

Mechanism of Action

Stage of Development

Advanced Solid Tumors

R/R Lymphomas

This information is current as of November 10th 2025.